Back to search

National and Kapodistrian University of Athens

Επίπεδα αγγειογενετικών αυξητικών παραγόντων στον ορό ασθενών με μη μικροκυτταρικό καρκίνο πνεύμονα πριν και μετά τη χορήγηση ανοσοθεραπείας, προγνωστική και προβλεπτική αξία

Abstract

dc:description

A complex interplay between immune cells and abnormal tumor vasculature in the tumor microenvironment has been previously shown in preclinical studies, while clinical data suggest that angiogenesis biomarkers may be useful as predictors of prognosis and treatment response in immunotherapy-treated solid tumors, including non-small cell lung cancer (NSCLC). Our primary aim was to investigate the prognostic and predictive value of baseline and post-treatment levels of serum vascular endothelial growth factor-A and –B (VEGF-A and VEGF-B, respectively), soluble programmed cell death-1 (sPD-1) and programmed cell death-ligand 1 (sPD-L1) in patients with advanced NSCLC treated with immune checkpoint inhibitors (ICIs). 55 patients with advanced NSCLC eligible to receive ICIs (as monotherapy or in combination with chemotherapy) were prospectively enrolled. A group of sex- and age-matched healthy controls (n=16) was also recruited, for determination of the optimal cut-offs and the potential diagnostic value of the examined biomarkers. Serum VEGF-A, VEGF-B, sPD-1 and sPD-L1 levels were measured in peripheral blood samples using ELISA, both at baseline and at the time of treatment response evaluation, and were correlated with treatment response, prognosis (PFS, OS), and the remaining clinicopathological features of patients. The mean age of patients was 66.5 years (SD=8.0 years); 65.5% of patients received chemotherapy and pembrolizumab combination while the remaining patients received pembrolizumab monotherapy. VEGF-B and sPD-1 levels were significantly decreased and increased, respectively, after treatment (p=0.028 and p<0.001, respectively). VEGF-A and sPD-L1 levels also decreased and increased, respectively, albeit without reaching statistical significance. ROC analysis showed that only VEGF-B and sPD-1 had significant value in discriminating between patients and controls. Univariate Cox regression analysis showed that increased pre-treatment values of sPD-1 (HR=10.96; p=0.037) and sPD-L1 (HR=1.68; p=0.040) and increased post-treatment levels of VEGF-B (HR=2.99; p=0.049) were all significantly associated with reduced OS. VEGF-B and sPD-L1 retained their prognostic significance in multivariate analysis (HR=3.37; p=0.032 and HR=2.10; p=0.014, respectively). The results of the study revealed that sPD-L1 and VEGF-B may represent independent biomarkers of prognosis in advanced-stage NSCLC patients treated with ICIs.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2025

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Kokkotou, Eleni
  • Κόκκοτου, Ελένη

Subjects

dc:subject × 14

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/60242

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Kokkotou, Eleni; Κόκκοτου, Ελένη. Επίπεδα αγγειογενετικών αυξητικών παραγόντων στον ορό ασθενών με μη μικροκυτταρικό καρκίνο πνεύμονα πριν και μετά τη χορήγηση ανοσοθεραπείας, προγνωστική και προβλεπτική αξία. National and Kapodistrian University of Athens, 2025. http://hdl.handle.net/10442/hedi/60242